TD Cowen keeps a Buy rating and $80 price target on CVS. The firm says the DOJ complaint relating to opioid prescriptions is incremental to the 2022 settlement with state and local governments for $5B over 10 years. The multi-year impasse between the DOJ and CVS suggests CVS is confident in its case, and while it is unclear what a final settlement figure may be, it may be a fraction of the $5B 10-year settlement that CVS came to with state and local governments in 2022, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CVS:
- Republicans spending package includes no PBM reform, Punchbowl says
- CVS Health price target lowered to $63 from $77 at BofA
- DoJ accuses CVS of filling, billing government for illegal opioid prescriptions
- CVS Health price target lowered to $51 from $57 at Leerink
- Trump Trade: Analyst says Trump win ‘not as positive as you’d think’ for Tesla
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
